Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
45 hedge funds and large institutions have $151M invested in Kaleido Biosciences, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 7 closing their positions.
24% more capital invested
Capital invested by funds: $122M → $151M (+$28.8M)
0% more funds holding
Funds holding: 45 → 45 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.23M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$789K |
| 3 |
Invesco
Atlanta,
Georgia
|
+$539K |
| 4 |
BlackRock
New York
|
+$338K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$561K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$377K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$291K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$131K |
| 5 |
BII
Bainco International Investors
Boston,
Massachusetts
|
-$108K |
KLDO Hedge Fund Activity: Q1 2020 in Review
45 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q1 2020, worth a combined $151M — up 24% from $122M a quarter earlier.
Fund positioning in KLDO was balanced in Q1 2020: 7 funds opened new positions, 7 closed out, 13 added to existing stakes and 14 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.23M. The largest seller was Goldman Sachs, exiting entirely with an estimated $561K sold.
- 45 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $151M of Kaleido Biosciences, Inc. Common Stock stock for Q1 2020, up 24% quarter-over-quarter.
- 7 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q1 2020 and 7 closed out, a net change of 0 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q1 2020 was Fidelity Investments, an estimated $1.23M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q1 2020 was Goldman Sachs, an estimated $561K sold.
Based on aggregated 13F filings for Q1 2020.